BioCentury
ARTICLE | Company News

GSK submits albiglutide MAA

March 8, 2013 1:37 AM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) submitted an MAA to EMA for Eperzan albiglutide to treat Type II diabetes. The pharma submitted an NDA to FDA for the product in January. GSK gained the fusion ...